The activity of micafungin against clinical isolates of non-albicans Candida spp.

• Authors: Anna Biernasiuk , Ewelina Dobiecka , Grazyna Zdzienicka , Anna Malm
• Languages of publication: EN

Abstracts

EN

Infections caused by non-albicans Candida spp. are an important medical problem in people from risk groups, e.g. hematooncological patients. The aim of this paper was to analyse the in vitro activity of micafungin against 30 clinical isolates of non-albicans Candida spp. (C. glabrata, C. famata, C. tropicalis, C. inconspicua, C. lusitaniae, C. parapsilosis, C. krusei) by way of the E-test procedure, allowing determination of minimal inhibitory concentration (MIC). Data presented in this paper indicate that most of the studied clinical isolates - 27 (90%) showed sensitivity to micafungin, with MIC values ranging from 0.004 to 2 mg/l, while 3 (10%) isolates, including 2 isolates of C. tropicalis and 1 isolate of C. famata, were resistant to micafungin, with MIC values > 32 mg/l. The MIC50 and MIC90 values of micafungin, defined as MIC inhibited growth of 50% or 90% of the isolates studied, were 0.008 mg/l or 2 mg/l, respectively. In the case of C. glabrata isolates, MICs ranged from 0.004 to 0.016 mg/l, while MIC50 was 0.004 mg/l and MIC90 - 0.008 mg/l. Our data confirm the utility of micafungin for the therapy of the infections caused by non-albicans Candida spp., especially C. glabrata.

Keywords

EN

micafungin; non-albicans Candida spp.; E-test; minimal inhibitory concentration (MIC)

• Publisher: De Gruyter Open
• Journal: Current Issues in Pharmacy and Medical Sciences
• Year: 2015
• Volume: 28
• Issue: 1
• Pages: 13-16

Dates

published

1 - 3 - 2015

accepted

12 - 3 - 2015

received

2 - 3 - 2015

online

9 - 5 - 2015

Contributors

author

Anna Biernasiuk

• Department of Pharmaceutical Microbiology, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

author

Ewelina Dobiecka

• Department of Pharmaceutical Microbiology, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

author

Grazyna Zdzienicka

• Department of Diagnostics Microbiology, Independent Public Teaching Hospital No 1, Staszica 16, 20-081 Lublin, Poland

author

Anna Malm

• Department of Pharmaceutical Microbiology, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

References

• 1. Abuhammour W., Habte-Gaber E.: Newer antifungal agents. Indian. J. Pediatr., 71, 253, 2004.[Crossref]
• 2. Andes D.R. et al.: In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother., 52, 3497, 2008.
• 3. Arendrup M.C. et al.: European Committee for Antimicrobial Susceptibility Testing (EUCAST). Methods for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. EUCAST definitive document EDef 7.2 Revision. March 2012.
• 4. Baran E., Dyląg M.: Echinokandyny - wielkocząsteczkowe lipopeptydy o aktywności przeciwgrzybiczej. Przegl. Dermatol., 93, 131, 2006.
• 5. Barry A.L. et al.: Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol., 38, 3457, 2000.
• 6. Bennett J.E., Izumikawa K., Marr K.A.: Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother., 48, 1773, 2004.
• 7. Bormann A.M., Morrison V.A.: Review of the pharmacology and clinical studies of micafungin. Drug Des. Devel. Ther., 29, 295, 2009.[Crossref]
• 8. Carter N.J., Keating G.M.: Micafungin: A review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. Paediatr Drugs., 11, 271, 2009.
• 9. Chandrasekar P.H., Sobel J.D.: Micafungin: A new echinocandin. Clin. Infect. Dis., 42, 1171, 2006.[Crossref]
• 10. Chion Ch., Groll A., Walsh T.: New drugs and novel targets for treatment of invasive fungal infections. Oncologist., 2, 120, 2000.
• 11. Choi H.W. et al.: In vitro susceptibilities to caspofungin and micafungin of clinical isolates of Candida species. Korean J. Lab. Med., 26, 275, 2006.
• 12. Dzierżanowska D.: Nowe antybiotyki stosowane w terapii inwazyjnych zakażeń grzybiczych. Zakażenia, 8, 34, 2008.
• 13. Dzierżanowska D. (2007). Patogeny zakażeń szpitalnych. Bielsko- Biała: α-medicapress.
• 14. Dzierżanowska D. (2007). Postacie kliniczne zakażeń szpitalnych. Bielsko-Biała: α-medicapress.
• 15. Eschenauer G., de Pestel D.D., Carver P.L.: Comparison of echinocandin antifungals. Ther. Clin. Risk. Manag., 3, 71, 2007.[Crossref]
• 16. Hashimoto S.: Micafungin: A sulfated echinocandin. J. Antibiot., 62, 27, 2009.[Crossref]
• 17. Ikeda F. et al.: Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med. Mycol., 47, 145, 2009.[WoS][Crossref]
• 18. Joseph J.M., Jain R., Danziger L.H.: Micafungin: A new echinocandin antifungal. Pharmacother., 27, 53, 2007.[Crossref]
• 19. Karthaus M., Cornely O.A.: Treatment options in candidaemia. Mycoses, 50, 44, 2007.[WoS][Crossref]
• 20. Messer S.A. et al.: Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol., 44, 324, 2006.[Crossref]
• 21. Morris M.I., Villmann M.: Echinocandins in the management of invasive fungal infections. Am. J. Health-Syst. Pharm., 63, 1693, 2006.[Crossref]
• 22. Nakai T. et al: In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelia forms. Antimicrob. Agents Chemother., 47, 1376, 2003.
• 23. Nguyen K.T. et al.: Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates. Int. J. Antimicrob. Agents., 35, 80, 2010.[WoS][Crossref]
• 24. Oliveira E.R. et al.: Antifungal susceptibility testing of micafungin against Candida glabrata isolates. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 105, 457, 2008.
• 25. Pappas P.G. et al.: Micafungin versus caspofungin for treatment of candidaemia and other forms of invasive candidiasis. Clin. Infect. Dis., 45, 883, 2007.[Crossref]
• 26. Pfaller M.A. et al.: Wild-type MIC distributions and epidemiological cut off values for the echinocandins and Candida spp. J. Clin. Microbiol., 48, 52, 2010.[Crossref]
• 27. Pfaller M.A. et al.: In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin and micafungin: Six years of global surveillance. J. Clin. Microbiol., 46, 150, 2008.[Crossref][WoS]
• 28. Pfaller M.A. et al.: Global surveillance of in vitro activity of micafungin against Candida: A comparison with caspofungin by CLSI - recommended methods. J. Clin. Microbiol., 44, 3533, 2006.[Crossref]
• 29. Pfaller M.A. et al.: Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol., 46, 2620, 2008.[WoS][Crossref]
• 30. Pfeiffer C.D. et al.: Breakthrough invasive candidiasis on micafungin. J. Clin. Microbiol., 48, 2373, 2010.[Crossref]
• 31. Prasad R., Kappor K.: Multidrug resistance in yeasts Candida. Int. Rev. Cytol., 242, 215, 2005.[Crossref]
• 32. Quindos G. et al.: In vitro antifungal activity of micafungin. Rev. Iberoam. Micol., 26, 35, 2009.[Crossref][WoS]
• 33. Quindos G., Villar-Vidal M., Eraso E.: Activity of micafungin against Candida biofilms. Rev. Iberoam. Micol., 26, 49, 2009.[WoS]
• 34. Resende M.A. et al.: Prevalence and antifungal susceptibility of yeasts obtained from the oral cavity of elderly individuals. Mycopathologia, 162, 39, 2006.[Crossref]
• 35. Sucher A.J., Chahine E.B., Balcer H.E.: Echinocandins: The newest class of antifungals. Ann. Pharmacother., 43, 1647, 2009.[WoS][Crossref]
• 36. Temesgen Z., Barreto J., Vento S.: Micafungin - the newest echinocandin. Drugs Today, 45, 469, 2009.[WoS][Crossref]
• 37. Turner M.S., Drew R.H., Perfect J.R.: Emerging echinocandins for treatment of invasive fungal infections. Expert Opin. Emerg. Drugs., 11, 231, 2006.[Crossref]
• 38. White T.C. et al.: Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother., 46, 1704, 2002.

Identifiers

DOI

10.1515/cipms-2015-0033